Delcath Systems, Inc. Share Price & Technical Analysis
DCTH · $10.59 (+2.52%)
Healthcare / Medical Devices
$10.59
+2.52%
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development …
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-5% return in Jun, -8% avg return in past 3 year Jun month.
4% return in 2026, 64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | -10% | 7% | 11% | 4% | -5% | – | – | – | – | – | – | 4% |
| 25 | 28% | -7% | -11% | -5% | 34% | -16% | -21% | 4% | 0% | -9% | -1% | 6% | 2% |
| 24 | 14% | -12% | 14% | 8% | 37% | 18% | 4% | 28% | -17% | 21% | 8% | 3% | 126% |
| 23 | 3% | 39% | 18% | -3% | 40% | -27% | -24% | 7% | -11% | -20% | -12% | 56% | 65% |
| 22 | -13% | -6% | -3% | -8% | -23% | -13% | 8% | 0% | -26% | -6% | 0% | 29% | -61% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$361.79M
P/E ratio
1048
52W high
$17.35
52W low
$8.12
Volume
8,287
Beta
0.54
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Delcath Systems, Inc. share price today?
- Delcath Systems, Inc. (DCTH) last traded around $10.59 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DCTH have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DCTH. Download the app for real-time alerts.
- How can I analyze Delcath Systems, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.